{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T13:09:49Z","timestamp":1792588189461,"version":"4.5.0"},"reference-count":56,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2019,8]]},"DOI":"10.1016\/j.ctrv.2019.06.003","type":"journal-article","created":{"date-parts":[[2019,6,22]],"date-time":"2019-06-22T10:22:49Z","timestamp":1561198969000},"page":"1-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":65,"special_numbering":"C","title":["FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma"],"prefix":"10.1016","volume":"78","author":[{"given":"Amit","family":"Mahipal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sri Harsha","family":"Tella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuhya","family":"Kommalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Anaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2019.06.003_b0005","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1053\/j.gastro.2009.02.038","article-title":"Burden of digestive diseases in the United States Part III: liver, biliary tract, and pancreas","volume":"136","author":"Everhart","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.ctrv.2019.06.003_b0010","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1080\/13543784.2018.1512581","article-title":"Novel targeted treatment options for advanced cholangiocarcinoma","volume":"27","author":"Mahipal","year":"2018","journal-title":"Exp Opin Invest Drugs"},{"key":"10.1016\/j.ctrv.2019.06.003_b0015","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1097\/01.sla.0000251366.62632.d3","article-title":"Cholangiocarcinoma: thirty-one-year experience with 564 patients at a single institution","volume":"245","author":"DeOliveira","year":"2007","journal-title":"Ann Surg"},{"key":"10.1016\/j.ctrv.2019.06.003_b0020","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1634\/theoncologist.2015-0446","article-title":"Forty-Year Trends in Cholangiocarcinoma Incidence in the U.S.: intrahepatic Disease on the Rise","volume":"21","author":"Saha","year":"2016","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2019.06.003_b0025","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1038\/ng.2806","article-title":"Exome sequencing identifies distinct mutational patterns in liver fluke-related and non-infection-related bile duct cancers","volume":"45","author":"Chan-On","year":"2013","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2019.06.003_b0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2019.06.003_b0035","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1158\/2159-8290.CD-17-0368","article-title":"Whole-genome and epigenomic landscapes of etiologically distinct subtypes of cholangiocarcinoma","volume":"7","author":"Jusakul","year":"2017","journal-title":"Cancer Disc"},{"key":"10.1016\/j.ctrv.2019.06.003_b0040","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41416-018-0334-0","article-title":"Derazantinib (ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive intrahepatic cholangiocarcinoma","volume":"120","author":"Mazzaferro","year":"2019","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.06.003_b0045","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/wdev.176","article-title":"The Fibroblast Growth Factor signaling pathway","volume":"4","author":"Ornitz","year":"2015","journal-title":"Wiley Interdisc Rev Dev Biol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0050","first-page":"753","article-title":"Fibroblast growth factors in epithelial repair and cytoprotection","volume":"359","author":"Braun","year":"2004","journal-title":"Philosoph Trans Roy Soc Lond Ser B, Biol Sci"},{"key":"10.1016\/j.ctrv.2019.06.003_b0055","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10741-007-9027-0","article-title":"Fibroblast growth factor-2 and cardioprotection","volume":"12","author":"Kardami","year":"2007","journal-title":"Heart Fail Rev"},{"key":"10.1016\/j.ctrv.2019.06.003_b0060","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.semcdb.2012.09.015","article-title":"The roles of receptor tyrosine kinases and their ligands in the wound repair process","volume":"23","author":"Muller","year":"2012","journal-title":"Semin Cell Dev Biol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0065","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1038\/35039551","article-title":"Crystal structure of fibroblast growth factor receptor ectodomain bound to ligand and heparin","volume":"407","author":"Pellegrini","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2019.06.003_b0070","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1038\/nrc2780","article-title":"Fibroblast growth factor signalling: from development to cancer","volume":"10","author":"Turner","year":"2010","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.06.003_b0075","doi-asserted-by":"crossref","first-page":"639","DOI":"10.2174\/156800909789057006","article-title":"The role of fibroblast growth factors in tumor growth","volume":"9","author":"Korc","year":"2009","journal-title":"Curr Cancer Drug Targ"},{"key":"10.1016\/j.ctrv.2019.06.003_b0080","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1541-7786.MCR-12-0275","article-title":"Macrophages promote fibroblast growth factor receptor-driven tumor cell migration and invasion in a CXCR2-dependent manner","volume":"10","author":"Bohrer","year":"2012","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.ctrv.2019.06.003_b0085","doi-asserted-by":"crossref","first-page":"1855","DOI":"10.1158\/1078-0432.CCR-11-0699","article-title":"Molecular pathways: fibroblast growth factor signaling: a new therapeutic opportunity in cancer","volume":"18","author":"Brooks","year":"2012","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.003_b0090","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1158\/0008-5472.CAN-09-3746","article-title":"FGFR1 amplification drives endocrine therapy resistance and is a therapeutic target in breast cancer","volume":"70","author":"Turner","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.003_b0095","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1002\/hep.26890","article-title":"Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma","volume":"59","author":"Arai","year":"2014","journal-title":"Hepatology (Baltimore, MD)"},{"key":"10.1016\/j.ctrv.2019.06.003_b0100","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1093\/hmg\/dds486","article-title":"Oncogenic FGFR3 gene fusions in bladder cancer","volume":"22","author":"Williams","year":"2013","journal-title":"Hum Mol Genet"},{"key":"10.1016\/j.ctrv.2019.06.003_b0105","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1634\/theoncologist.2013-0352","article-title":"New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing","volume":"19","author":"Ross","year":"2014","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2019.06.003_b0110","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2014.02.050","article-title":"Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma","volume":"446","author":"Xu","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.ctrv.2019.06.003_b0115","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.1074\/jbc.M115.698472","article-title":"A hippo and fibroblast growth factor receptor autocrine pathway in cholangiocarcinoma","volume":"291","author":"Rizvi","year":"2016","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2019.06.003_b0120","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1016\/j.jhep.2018.01.026","article-title":"Fibroblast growth factor receptor inhibition induces loss of matrix MCL1 and necrosis in cholangiocarcinoma","volume":"68","author":"Kabashima","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0125","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1158\/2159-8290.CD-13-0050","article-title":"Identification of targetable FGFR gene fusions in diverse cancers","volume":"3","author":"Wu","year":"2013","journal-title":"Cancer Disc"},{"key":"10.1016\/j.ctrv.2019.06.003_b0130","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1016\/j.humpath.2014.03.014","article-title":"Fibroblast growth factor receptor 2 translocations in intrahepatic cholangiocarcinoma","volume":"45","author":"Graham","year":"2014","journal-title":"Hum Pathol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1200\/PO.17.00080","article-title":"Cholangiocarcinoma with FGFR genetic aberrations: a unique clinical phenotype","author":"Jain","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0140","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1200\/JCO.2016.67.2048","volume":"35","author":"Nogova","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0145","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1200\/JCO.2017.75.5009","article-title":"Phase II study of BGJ398 in patients With FGFR-altered advanced cholangiocarcinoma","volume":"36","author":"Javle","year":"2018","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0150","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy424.030","article-title":"LBA28Updated results from a phase II study of infigratinib (BGJ398), a selective pan-FGFR kinase inhibitor, in patients with previously treated advanced cholangiocarcinoma containing FGFR2 fusions","volume":"29","author":"Javle","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0155","doi-asserted-by":"crossref","first-page":"e0162594","DOI":"10.1371\/journal.pone.0162594","article-title":"Preclinical activity of ARQ 087, a Novel inhibitor targeting FGFR dysregulation","volume":"11","author":"Hall","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctrv.2019.06.003_b0160","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/bjc.2017.330","article-title":"A Phase 1 study of ARQ 087, an oral pan-FGFR inhibitor in patients with advanced solid tumours","volume":"117","author":"Papadopoulos","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.06.003_b0165","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.1200\/JCO.2017.35.15_suppl.4074","article-title":"Safety and activity of the pan-fibroblast growth factor receptor (FGFR) inhibitor erdafitinib in phase 1 study patients (Pts) with molecularly selected advanced cholangiocarcinoma (CCA)","volume":"35","author":"Soria","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0170","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdy149","article-title":"O-001Efficacy of TAS-120, an irreversible fibroblast growth factor receptor (FGFR) inhibitor, in cholangiocarcinoma patients with FGFR pathway alterations who were previously treated with chemotherapy and other FGFR inhibitors","volume":"29","author":"Meric-Bernstam","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0175","doi-asserted-by":"crossref","first-page":"CT111-CT","DOI":"10.1158\/1538-7445.AM2017-CT111","article-title":"Abstract CT111: preliminary results from a phase 1\/2 study of INCB054828, a highly selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced malignancies","volume":"77","author":"Saleh","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.003_b0180","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2017.35.15_suppl.TPS4145","article-title":"Phase 2, open-label, multicenter study of the efficacy and safety of INCB054828 in patients (pts) with advanced, metastatic, or surgically unresectable cholangiocarcinoma (CCA) with inadequate response to prior therapy","volume":"35","author":"Borad","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0185","volume":"29","author":"Hollebecque","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0190","doi-asserted-by":"crossref","first-page":"TPS462-TPS","DOI":"10.1200\/JCO.2019.37.4_suppl.TPS462","article-title":"Trial design for a phase 3 study evaluating pemigatinib (INCB054828) versus gemcitabine plus cisplatin chemotherapy in first-line treatment of patients with cholangiocarcinoma with FGFR2 rearrangement","volume":"37","author":"Bekaii-Saab","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0195","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s10637-016-0416-x","article-title":"Safety, tolerability and pharmacokinetics of the fibroblast growth factor receptor inhibitor AZD4547 in Japanese patients with advanced solid tumours: a Phase I study","volume":"35","author":"Saka","year":"2017","journal-title":"Invest New Drugs"},{"key":"10.1016\/j.ctrv.2019.06.003_b0200","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.06.003_b0205","doi-asserted-by":"crossref","first-page":"17044","DOI":"10.1038\/nrdp.2017.44","article-title":"Tumour-induced osteomalacia","volume":"3","author":"Minisola","year":"2017","journal-title":"Nat Rev Dis Prim"},{"key":"10.1016\/j.ctrv.2019.06.003_b0210","first-page":"e1","article-title":"Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations","volume":"34","author":"Mellor","year":"2014","journal-title":"Liver Int Off J Int Assoc Study Liver"},{"key":"10.1016\/j.ctrv.2019.06.003_b0215","doi-asserted-by":"crossref","first-page":"16052","DOI":"10.18632\/oncotarget.14109","article-title":"Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application","volume":"8","author":"Chae","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctrv.2019.06.003_b0220","doi-asserted-by":"crossref","first-page":"TPS532-TPS","DOI":"10.1200\/JCO.2018.36.4_suppl.TPS532","article-title":"A pilot study of ponatinib in cholangiocarcinoma patients with FGFR2 fusions","volume":"36","author":"DeLeon","year":"2018","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0225","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/bjc.2017.119","article-title":"The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma","volume":"116","author":"Shroff","year":"2017","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ctrv.2019.06.003_b0230","doi-asserted-by":"crossref","first-page":"5750","DOI":"10.1158\/1078-0432.CCR-10-0531","article-title":"Monoclonal antibodies to fibroblast growth factor receptor 2 effectively inhibit growth of gastric tumor xenografts","volume":"16","author":"Zhao","year":"2010","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.003_b0235","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1038\/nrc1716","article-title":"HSP90 and the chaperoning of cancer","volume":"5","author":"Whitesell","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2019.06.003_b0240","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1016\/j.cellsig.2011.06.010","article-title":"The driver of malignancy in KG-1a leukemic cells, FGFR1OP2-FGFR1, encodes an HSP90 addicted oncoprotein","volume":"23","author":"Jin","year":"2011","journal-title":"Cell Signal"},{"key":"10.1016\/j.ctrv.2019.06.003_b0245","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1158\/1541-7786.MCR-14-0004","article-title":"FGFR3 translocations in bladder cancer: differential sensitivity to HSP90 inhibition based on drug metabolism","volume":"12","author":"Acquaviva","year":"2014","journal-title":"Mol Cancer Res MCR"},{"key":"10.1016\/j.ctrv.2019.06.003_b0250","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1158\/2159-8290.CD-12-0440","article-title":"Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer","volume":"3","author":"Sang","year":"2013","journal-title":"Cancer Disc"},{"key":"10.1016\/j.ctrv.2019.06.003_b0255","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1158\/2159-8290.CD-16-1000","article-title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","volume":"7","author":"Goyal","year":"2017","journal-title":"Cancer discovery"},{"key":"10.1016\/j.ctrv.2019.06.003_b0260","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1200\/JCO.2016.70.5061","article-title":"Genome-driven paradigm for the development of selective fibroblast growth factor receptor inhibitors","volume":"35","author":"Schram","year":"2017","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0265","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/s41571-018-0115-y","article-title":"Fibroblast growth factor receptors as treatment targets in clinical oncology","volume":"16","author":"Katoh","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.ctrv.2019.06.003_b0270","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1158\/0008-5472.CAN-03-1022","article-title":"Genomic and expression analysis of the 8p11-12 amplicon in human breast cancer cell lines","volume":"64","author":"Ray","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2019.06.003_b0275","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1158\/2159-8290.CD-15-1246","article-title":"High-level clonal FGFR amplification and response to FGFR inhibition in a translational clinical trial","volume":"6","author":"Pearson","year":"2016","journal-title":"Cancer Disc"},{"key":"10.1016\/j.ctrv.2019.06.003_b0280","doi-asserted-by":"crossref","first-page":"A072-A","DOI":"10.1158\/1535-7163.TARG-17-A072","article-title":"Abstract A072: Effect of pharmacologic inhibition of mutant IDH in cholangiocarcinoma","volume":"17","author":"Saha","year":"2018","journal-title":"Mol Cancer Ther"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300817?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737219300817?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:20:19Z","timestamp":1759656019000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737219300817"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":56,"alternative-id":["S0305737219300817"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.003","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2019,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"FGFR2 genomic aberrations: Achilles heel in the management of advanced cholangiocarcinoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2019.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}